

Adam Pluzanski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4172319/publications.pdf>

Version: 2024-02-01

30
papers

12,828
citations

567281

15
h-index

552781

26
g-index

30
all docs

30
docs citations

30
times ranked

15393
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 123-135.	27.0	7,261
2	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018, 378, 2093-2104.	27.0	2,469
3	Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2017, 18, 1454-1466.	10.7	877
4	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and 057). <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	1.6	361
5	Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 2244-2250.	1.6	329
6	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	1.6	329
7	Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. <i>Lancet Oncology</i> , 2019, 20, 1395-1408.	10.7	247
8	First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial. <i>Journal of Thoracic Oncology</i> , 2022, 17, 289-308.	1.1	173
9	Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , 2014, 15, 1369-1378.	10.7	124
10	Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. <i>Journal of Clinical Oncology</i> , 2021, 39, 257-266.	10.9	57
11	Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1. <i>Journal of Clinical Oncology</i> , 2020, 38, 9500-9500.	1.6	42
12	Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). <i>Journal of Clinical Oncology</i> , 2016, 34, 9038-9038.	1.6	31
13	Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 2795-2805.	2.4	27
14	Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA9007-LBA9007.	1.6	21
15	Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. <i>ESMO Open</i> , 2020, 5, e001011.	4.5	15
16	Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response. <i>Cancer Research</i> , 2019, 79, CT195-CT195.	0.9	13
17	Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227. <i>Cancer Research</i> , 2018, 78, CT077-CT077.	0.9	11
18	Dacomitinib (daco) versus gefitinib (gef) for first-line treatment of advanced NSCLC (ARCHER 1050): Final overall survival (OS) analysis. <i>Journal of Clinical Oncology</i> , 2018, 36, 9004-9004.	1.6	9

#	ARTICLE	IF	CITATIONS
19	Assessing the impact of antiemetic guideline compliance on prevention of chemotherapy-induced nausea and vomiting (CINV): Results of the Nausea/Emesis Registry in Oncology (NERO).. Journal of Clinical Oncology, 2020, 38, 12083-12083.	1.6	6
20	Treatment patterns, testing practices, and outcomes in the pre-FLAURA era for patients with EGFR mutation-positive advanced NSCLC: a retrospective chart review (REFLECT). Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110598.	3.2	6
21	Do We Need TNM for Tracheal Cancers? Analysis of a Large Retrospective Series of Tracheal Tumors. Cancers, 2022, 14, 1665.	3.7	6
22	Crizotinib in the treatment of non-small-cell lung cancer [Polish version: Kryzotynib w leczeniu chorych na niedrobnokomórkowego raka płuca p. 485]. Współczesna Onkologia, 2012, 6, 480-490.	1.4	5
23	Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment. Journal of Clinical Medicine, 2022, 11, 1738.	2.4	4
24	Solitary fibrous tumour along with non-small-cell lung cancer and Doege-Potter syndrome. Kardiochirurgia i Torakochirurgia Polska, 2019, 16, 49-51.	0.1	3
25	Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial.. Journal of Clinical Oncology, 2017, 35, LBA9007-LBA9007.	1.6	3
26	A case of adenoid cystic carcinoma of trachea: treatment complications and radiotherapy role. Journal of Contemporary Brachytherapy, 2021, 13, 588-592.	0.9	2
27	The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050. Future Oncology, 2021, 17, 783-794.	2.4	0
28	Real-world outcomes and clinical characteristics of patients with brain metastases from EGFR mutated non-small cell lung cancer: Data from a large retrospective study (REFLECT).. Journal of Clinical Oncology, 2021, 39, 9086-9086.	1.6	0
29	Advanced solitary fibrous tumour of the pleura – a case report and literature review. Oncology in Clinical Practice, 2019, 15, 185-189.	0.1	0
30	Adenoid cystic carcinoma of the lung – a case report. Oncology in Clinical Practice, 2020, 15, 336-338.	0.1	0